To date in B cell NHL, two CD19-specific CAR-T cells axicel and tisagenlecleucel are FDA-approved to treat relapsed and refractory DLBCL after at least two lines of systemic therapy [125,126,127,128]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.